Literature DB >> 27063219

Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice.

Hung-I Lu1, Tien-Hung Huang2, Pei-Hsun Sung2, Yung-Lung Chen2, Sarah Chua2,3, Han-Yan Chai2, Sheng-Ying Chung2, Chu-Feng Liu4, Cheuk-Kwan Sun5, Hsueh-Wen Chang6, Yen-Yi Zhen2, Fan-Yen Lee1, Hon-Kan Yip2,3,7,8,9.   

Abstract

AIM: Antioxidant peptide SS-31 is a class of cell-permeable small peptides, which selectively resides on the inner mitochondrial membrane and possesses intrinsic mitochondrial protective capacities. In this study we investigated the therapeutic effects of antioxidant peptide SS-31 on transverse aortic constriction (TAC)-induced pulmonary arterial hypertension (PAH) in a murine model.
METHODS: Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d. The right ventricular systolic blood pressure (RVSBP) was measured on d 60 prior to sacrificing the mice; then their right heart and lung tissues were collected for histological and biochemical examinations. Lung injury scores were defined by the increased crowded area and decreased number of alveolar sacs.
RESULTS: TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice. The same pattern of changes was found in pulmonary levels of oxidative stress proteins (NOX-1/NOX-2/oxidized proteins), cytosolic cytochrome c, biomarkers related to inflammation (MMP-9/TNF-α/iNOS), calcium overload index (TRPC1, 2, 4, 6), apoptosis (mitochondrial BAX, cleaved caspase 3/PARP), fibrosis (Smad3/TGF-β), hypoxic (HIF-1α), DNA damage (γ-H2AX) and endothelial function (eNOS/ET-1R), as well as in lung injury score, number of muscularized vessels in lungs, number of TRPC1(+) and HIF-1α(+) cells in pulmonary artery, and number of γ-H2AX(+) and Ki-67(+) cells in lung parenchyma. An opposite pattern of changes was observed in pulmonary anti-fibrotic markers (Smad1/5, BMP-2), number of small vessels, and number of alveolar sacs. In contrast, the levels of antioxidant proteins (HO-1/NQO-1/GR/GPx) in lung parenchyma were progressively and significantly increased from sham-operated mice, TAC mice to TAC+SS-31 mice.
CONCLUSION: Antioxidant peptide SS-31 administration effectively attenuates TAC-induced PAH in mice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27063219      PMCID: PMC4857546          DOI: 10.1038/aps.2015.162

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  29 in total

1.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.

Authors:  Cynthia Binanay; Robert M Califf; Vic Hasselblad; Christopher M O'Connor; Monica R Shah; George Sopko; Lynne W Stevenson; Gary S Francis; Carl V Leier; Leslie W Miller
Journal:  JAMA       Date:  2005-10-05       Impact factor: 56.272

2.  Impact of pulmonary artery catheter on outcome in patients with acute heart failure syndromes with hypotension or receiving inotropes: from the ATTEND Registry.

Authors:  Yohei Sotomi; Naoki Sato; Katsuya Kajimoto; Yasushi Sakata; Masayuki Mizuno; Yuichiro Minami; Kenshi Fujii; Teruo Takano
Journal:  Int J Cardiol       Date:  2014-01-09       Impact factor: 4.164

3.  Economic evaluation of Manitoba Health Lines in the management of congestive heart failure.

Authors:  Yang Cui; Malcolm Doupe; Alan Katz; Paul Nyhof; Evelyn L Forget
Journal:  Healthc Policy       Date:  2013-11

4.  Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines.

Authors:  Kesheng Zhao; Guoxiong Luo; Serena Giannelli; Hazel H Szeto
Journal:  Biochem Pharmacol       Date:  2005-10-10       Impact factor: 5.858

Review 5.  Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.

Authors:  Christophe Meune; Karim Wahbi; Denis Duboc; Simon Weber
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-12-30       Impact factor: 2.457

6.  Impact of home versus clinic-based management of chronic heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial.

Authors:  Simon Stewart; Melinda J Carrington; Thomas H Marwick; Patricia M Davidson; Peter Macdonald; John D Horowitz; Henry Krum; Phillip J Newton; Christopher Reid; Yih Kai Chan; Paul A Scuffham
Journal:  J Am Coll Cardiol       Date:  2012-10-02       Impact factor: 24.094

Review 7.  Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury.

Authors:  Hazel H Szeto
Journal:  Antioxid Redox Signal       Date:  2008-03       Impact factor: 8.401

8.  The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.

Authors:  Alexander V Birk; Shaoyi Liu; Yi Soong; William Mills; Pradeep Singh; J David Warren; Surya V Seshan; Joel D Pardee; Hazel H Szeto
Journal:  J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 10.121

9.  Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study).

Authors:  Patricia P Chang; Lloyd E Chambless; Eyal Shahar; Alain G Bertoni; Stuart D Russell; Hanyu Ni; Max He; Thomas H Mosley; Lynne E Wagenknecht; Tandaw E Samdarshi; Lisa M Wruck; Wayne D Rosamond
Journal:  Am J Cardiol       Date:  2013-11-09       Impact factor: 2.778

10.  Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury.

Authors:  Hon-Kan Yip; Yi-Chih Chang; Christopher Glenn Wallace; Li-Teh Chang; Tzu-Hsien Tsai; Yung-Lung Chen; Hsueh-Wen Chang; Steve Leu; Yen-Yi Zhen; Ching-Yen Tsai; Kuo-Ho Yeh; Cheuk-Kwan Sun; Chia-Hung Yen
Journal:  J Pineal Res       Date:  2012-10-30       Impact factor: 13.007

View more
  20 in total

1.  SS31 therapy effectively protects the heart against transverse aortic constriction-induced hypertrophic cardiomyopathy damage.

Authors:  Hung-I Lu; Fan-Yen Lee; Christopher Glenn Wallace; Pei-Hsun Sung; Kuan-Hung Chen; Jiunn-Jye Sheu; Sarah Chua; Meng-Shen Tong; Tien-Hung Huang; Yi-Ling Chen; Pei-Lin Shao; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Entresto therapy effectively protects heart and lung against transverse aortic constriction induced cardiopulmonary syndrome injury in rat.

Authors:  Hung-I Lu; Meng-Shen Tong; Kuan-Hung Chen; Fan-Yen Lee; John Y Chiang; Sheng-Ying Chung; Pei-Hsun Sung; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

3.  Role of double knockdown of tPA and MMP-9 on regulating the left ventricular function and remodeling followed by transverse aortic constriction-induced hypertrophic cardiomyopathy in mice.

Authors:  Pei-Hsun Sung; Sarah Chua; Kuan-Hung Chen; Cheuk-Kwan Sun; Yi-Chen Li; Chi-Ruei Huang; Chi-Wen Luo; Han-Tan Chai; Hung-I Lu; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

4.  Novel Therapeutic Approaches of Pulmonary Arterial Hypertension.

Authors:  Sanjay Tyagi; Vishal Batra
Journal:  Int J Angiol       Date:  2019-07-12

Review 5.  Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.

Authors:  Massimo Bonora; Mariusz R Wieckowski; David A Sinclair; Guido Kroemer; Paolo Pinton; Lorenzo Galluzzi
Journal:  Nat Rev Cardiol       Date:  2019-01       Impact factor: 32.419

Review 6.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

Review 7.  Mitochondrial complex I deficiency and cardiovascular diseases: current evidence and future directions.

Authors:  Maurizio Forte; Silvia Palmerio; Franca Bianchi; Massimo Volpe; Speranza Rubattu
Journal:  J Mol Med (Berl)       Date:  2019-03-12       Impact factor: 4.599

Review 8.  Inhibitors of Mitochondrial Dynamics Mediated by Dynamin-Related Protein 1 in Pulmonary Arterial Hypertension.

Authors:  Fan Xiao; Rui Zhang; Lan Wang
Journal:  Front Cell Dev Biol       Date:  2022-06-30

Review 9.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

10.  Mitochondrial-Targeting Antioxidant SS-31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke.

Authors:  De-Qing Yang; Qiu-Nan Zuo; Tao Wang; Dan Xu; Liu Lian; Li-Juan Gao; Chun Wan; Lei Chen; Fu-Qiang Wen; Yong-Chun Shen
Journal:  Oxid Med Cell Longev       Date:  2021-06-15       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.